Medical Condition News

RSS

Medtronic pacemaker reduces risk of syncope recurrence

Medtronic, Inc. today announced the results of a double-blind, randomized study, ISSUE-3, which found that patients who suffered from fainting due to neurocardiogenic syncope had fewer fainting occurrences when treated with a Medtronic pacemaker.

From Medtronic 27 Mar 2012

Study clarifies conflicting reports for clot aspiration and abciximab administration

The anti-platelet drug abciximab, delivered directly to lesions caused by a heart attack, significantly decreased damage to the heart muscle in high-risk patients while clot aspiration showed no impact, according to research presented today at the American College of Cardiology's 61st Annual Scientific Session.

From Medtronic 27 Mar 2012

ASBP releases weight-loss tips for patients with type 2 diabetes

The American Society of Bariatric Physicians (ASBP) today released a set of weight-loss tips that are effective for improving and reversing type 2 diabetes.

27 Mar 2012

Repeated stress triggers tau protein aggregates inside brain cells

Repeated stress triggers the production and accumulation of insoluble tau protein aggregates inside the brain cells of mice, say researchers at the University of California, San Diego School of Medicine in a new study published in the March 26 Online Early Edition of the Proceedings of the National Academy of Sciences.

27 Mar 2012

Study identifies major gene affecting chronic pain sensitivity

Nearly one in five people suffers from the insidious and often devastating problem of chronic pain.

27 Mar 2012

Bariatric surgery better than standard medical treatment for severe type 2 diabetes

In the first published study of its kind, researchers from the Catholic University/Policlinico Gemelli in Rome, Italy, and NewYork-Presbyterian/Weill Cornell Medical Center found that bariatric surgery dramatically outperforms standard medical treatment of severe type 2 diabetes.

27 Mar 2012

Simple OB/GYN screening may identify risk of heart disease among women

Simple screening implemented in obstetrics and gynecology (OB/GYN) clinics may identify previously undetected heart disease risk among women and has the potential to greatly increase education about prevention and treatment of cardiovascular disease in female patients, according to research presented today at the American College of Cardiology's 61st Annual Scientific Session.

27 Mar 2012

Novel interventional radiology procedure zaps around complicated pancreatic tumors

Results of a study presented at the Society of Interventional Radiology's 37th Annual Scientific Meeting in San Francisco, Calif., signal a light at the end of the tunnel for individuals with inoperable locally advanced pancreatic cancer (LAPC). A new procedure called irreversible electroporation or IRE uses microsecond electrical pulses to force open and destroy tumor cells around a vast and delicate network of blood vessels of the pancreas.

27 Mar 2012

Lowering LDL at younger age can reduce risk of CHD

Coronary atherosclerosis - a hardening of the arteries due to a build-up of fat and cholesterol - can lead to heart attacks and other forms of coronary heart disease (CHD). Lowering low-density lipoprotein (LDL), or "bad" cholesterol, reduces the risk of CHD, and researchers found that lowering LDL beginning early in life resulted in a three-fold greater reduction in the risk of CHD than treatment with a statin started later in life, according to research presented today at the American College of Cardiology's 61st Annual Scientific Session.

27 Mar 2012

Vaccine to prevent Campylobacter in chickens can help reduce food-borne illness

A vaccine could be developed to prevent Campylobacter being carried in chickens. This approach could drastically cut the number of cases of food poisoning, saving the UK economy millions each year, says an American scientist presenting his work at the Society for General Microbiology's Spring Conference in Dublin.

27 Mar 2012

Bolus intracoronary abciximab reduces infarct size in high-risk patients with STEMI

Administration of a bolus dose of the anticoagulant drug abciximab into the coronary artery involved in causing a certain type of heart attack among patients who were undergoing a percutaneous coronary intervention and also receiving another anticoagulant resulted in reduction in the size of damage to the heart muscle at 30 days, while a procedure that involved use of a catheter to remove the blood clot blocking that coronary artery did not produce these results, according to a study appearing in JAMA.

27 Mar 2012

FDA issues Complete Response letter to MAP's NDA for LEVADEX

MAP Pharmaceuticals, Inc. today announced that the United States Food and Drug Administration (FDA) has issued a Complete Response letter to its New Drug Application (NDA) for LEVADEX (dihydroergotamine) inhalation aerosol.

27 Mar 2012

Study finds imbalance between growth of PCI centers and the U.S. population

There is an imbalance between the rapid growth of cardiac catheterization laboratories, which provide percutaneous coronary intervention (PCI) procedures, relative to the growth in the overall U.S. population, as well as patients who experience an acute heart attack, or ST-elevation myocardial infarction (STEMI), according to a study presented March 25 at the 61st annual American College of Cardiology (ACC) scientific session.

27 Mar 2012

Medtronic Resolute DES found effective through two years

According to new clinical data presented today at ACC.12 -- the 61st Annual Scientific Session & Expo of the American College of Cardiology (ACC) -- the Resolute drug-eluting stent (DES) from Medtronic, Inc. maintains a powerful and persistent treatment effect for a wide variety of patients with coronary artery disease, including those with diabetes mellitus, through two years of follow-up.

From Medtronic 27 Mar 2012

Mayo Clinic researchers join expedition to Everest

It's a natural laboratory for studying heart disease, lung problems, muscle loss, sleeping disorders and new medical technologies. It's also the highest mountain in the world. Mount Everest's extreme altitude puts climbers under the same conditions experienced by patients suffering from heart disease, obesity or advanced age. To take advantage of that, Mayo Clinic researchers are joining an expedition to Everest with National Geographic, The North Face and Montana State University.

26 Mar 2012

NIH OBSSR creates Web-based interactive anthology

A Web-based interactive anthology will provide psychologists, economists, anthropologists, sociologists and other scientists with the latest research methods and tools to address emerging challenges in public health, such as the obesity epidemic and the rise of chronic diseases such as heart disease.

26 Mar 2012

Lower BMI increases risk during insertion of ICDs

Patients who are underweight or small in stature are twice as likely to experience complications or die during insertion of an implantable cardioverter-defibrillator (ICD) compared to obese and normal-weight patients, according to research presented today at the American College of Cardiology's 61st Annual Scientific Session.

26 Mar 2012

EMA accepts Arena's lorcaserin MAA for weight control

Arena Pharmaceuticals, Inc. announced today that the European Medicines Agency (EMA) has accepted the filing of a Marketing Authorization Application (MAA) for lorcaserin, an investigational drug candidate intended for weight control, including weight loss and maintenance of weight loss, in patients who are obese (BMI >30) or patients who are overweight (BMI >27) and have at least one weight-related co-morbid condition.

26 Mar 2012

CardioFocus introduces HeartLight Endoscopic Ablation System for AF in the Netherlands

CardioFocus, Inc., developer of the HeartLight Endoscopic Ablation System (EAS) for the treatment of atrial fibrillation (AF), announces its technology is now available in the Netherlands. Physicians at Isala Klinieken in Zwolle were the first in the country to incorporate visually guided ablation into their regular therapeutic practice and have successfully treated several patients.

26 Mar 2012

CSL Behring commences enrollment in SCIg PATH trial for CIDP

CSL Behring has announced that the first patient has been enrolled in the PATH study, an international clinical trial designed to evaluate the efficacy, safety, and tolerability of two different doses of subcutaneous immunoglobulin (SCIg), compared with placebo, in maintenance treatment of chronic inflammatory demyelinating polyneuropathy (CIDP).

26 Mar 2012